2WA0 | pdb_00002wa0

Crystal structure of the human MAGEA4

• PDB DOI: https://doi.org/10.2210/pdb2WA0/pdb

• Classification: IMMUNE SYSTEM
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)
• Mutation(s): No 


• Deposited: 2009-01-31 Released: 2009-03-10 
• Deposition Author(s): Roos, A.K., Cooper, C.D.O., Ugochukwu, E., W Yue, W., Berridge, G., Elkins, J.M., Pike, A.C.W., Bray, J., Filippakopoulos, P., Muniz, J., Chaikuad, A., Burgess-Brown, N., Arrowsmith, C.H., Weigelt, J., Edwards, A., Bountra, C., von Delft, F., Gileadi, O., Oppermann, U.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.30 Å
• R-Value Free: 
  0.274 (Depositor), 0.279 (DCC) 
• R-Value Work: 
  0.243 (Depositor), 0.241 (DCC) 
• R-Value Observed: 
  0.244 (Depositor) 

Literature

Structures of Two Melanoma-Associated Antigens Suggest Allosteric Regulation of Effector Binding.

Newman, J.A., Cooper, C.D.O., Roos, A.K., Aitkenhead, H., Oppermann, U.C.T., Cho, H.J., Osman, R., Gileadi, O.

(2016) PLoS One 11: 48762

• PubMed: 26910052 
• DOI: https://doi.org/10.1371/journal.pone.0148762
• Primary Citation Related Structures: 
  2WA0, 4V0P, 5HVQ


• PubMed Abstract: 
  

  The MAGE (melanoma associated antigen) protein family are tumour-associated proteins normally present only in reproductive tissues such as germ cells of the testis. The human genome encodes over 60 MAGE genes of which one class (containing MAGE-A3 and MAGE-A4) are exclusively expressed in tumours, making them an attractive target for the development of targeted and immunotherapeutic cancer treatments. Some MAGE proteins are thought to play an active role in driving cancer, modulating the activity of E3 ubiquitin ligases on targets related to apoptosis. Here we determined the crystal structures of MAGE-A3 and MAGE-A4. Both proteins crystallized with a terminal peptide bound in a deep cleft between two tandem-arranged winged helix domains. MAGE-A3 (but not MAGE-A4), is predominantly dimeric in solution. Comparison of MAGE-A3 and MAGE-A3 with a structure of an effector-bound MAGE-G1 suggests that a major conformational rearrangement is required for binding, and that this conformational plasticity may be targeted by allosteric binders.

---

Organizational Affiliation: 
• Structural Genomics Consortium, University of Oxford, ORCRB, Roosevelt Drive, Oxford, OX3 7DQ, United Kingdom.
NDORMS, University of Oxford, Botnar Research Centre, Oxford, OX3 7LD, United Kingdom.
Tisch Cancer Institute, Mt Sinai School of Medicine, Icahn 15-20B 1425 Madison Avenue, New York, NY, 10029, United States of America.
Department of Structural and Chemical Biology, Box 1677, Mount Sinai School of Medicine, New York, NY, 10029, United States of America.

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PQS (software)

Macromolecule Content 

• Total Structure Weight: 27.42 kDa 
• Atom Count: 1,749 
• Modeled Residue Count: 214 
• Deposited Residue Count: 240 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
MELANOMA-ASSOCIATED ANTIGEN 4	A	240	Homo sapiens	Mutation(s): 0
UniProt & NIH Common Fund Data Resources
Find proteins for P43358 (Homo sapiens) Explore P43358  Go to UniProtKB:  P43358
PHAROS:  P43358 GTEx:  ENSG00000147381

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.30 Å
• R-Value Free:  0.274 (Depositor), 0.279 (DCC) 
• R-Value Work:  0.243 (Depositor), 0.241 (DCC) 
• R-Value Observed: 0.244 (Depositor) 

Space Group: P 6₅ 2 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 81.63	α = 90
b = 81.63	β = 90
c = 210.891	γ = 120

Software Package:

Software Name	Purpose
MOSFLM	data reduction
SCALA	data scaling
SHELX	phasing
SHARP	phasing
REFMAC	refinement

Structure Validation

Entry History 

Deposition Data

• Released Date: 2009-03-10 
Deposition Author(s): Roos, A.K., Cooper, C.D.O., Ugochukwu, E., W Yue, W., Berridge, G., Elkins, J.M., Pike, A.C.W., Bray, J., Filippakopoulos, P., Muniz, J., Chaikuad, A., Burgess-Brown, N., Arrowsmith, C.H., Weigelt, J., Edwards, A., Bountra, C., von Delft, F., Gileadi, O., Oppermann, U.

Revision History  

• Version 1.0: 2009-03-10
  Type: Initial release
  
• Version 1.1: 2011-07-13
  Changes: Advisory, Version format compliance
• Version 1.2: 2015-04-29
  Changes: Data collection, Refinement description
• Version 1.3: 2016-03-09
  Changes: Database references
• Version 1.4: 2018-01-24
  Changes: Structure summary
• Version 1.5: 2024-05-08
  Changes: Data collection, Database references, Other